Table 1.
Patient and Treatment Characteristics
| Characteristic | Level | All Patients (N = 83) |
HCC (n = 44) |
ICC (N = 39) |
|---|---|---|---|---|
| % (No.) or Median (range) | % (No.) or Median (range) | % (No.) or Median (Range) | ||
| Age at radiation start date | 67.6 (29.9-89.7) | 70.5 (53.6-89.7) | 66.9 (29.9-87.0) | |
| Sex | Male | 61.4% (51) | 84.1% (37) | 35.9% (12) |
| Female | 38.6% (32) | 15.9% (7) | 64.1% (25) | |
| Race/ethnicity | White | 91.6% (76) | 90.9% (40) | 92.3% (36) |
| Black | 4.8% (4) | 4.5% (2) | 5.1% (2) | |
| Asian | 1.2% (1) | 0.0% (0) | 2.6% (1) | |
| Hispanic (white or black) | 1.2% (1) | 2.3% (1) | 0.0% (0) | |
| Unknown | 1.2% (1) | 2.3% (1) | 0.0% (0) | |
| Underlying liver disease | HCV (± others) | 33.7% (28) | 52.3% (13) | 12.8% (5) |
| No HCV but HBV (± others) | 7.2% (6) | 9.1% (4) | 5.1% (2) | |
| No HCV or HBV but EtOH (± others) | 9.6% (8) | 13.6% (6) | 5.1% (2) | |
| No HCV, HBV, or EtOH but NASH (± others) | 3.6% (3) | 4.5% (2) | 2.6% (1) | |
| Other | 2.4% (2) | 2.3% (1) | 2.6% (1) | |
| None | 43.4% (36) | 18.2% (8) | 71.8% (28) | |
| ECOG performance status | 0 | 33.7% (28) | 34.1% (14) | 33.3% (15) |
| 1 | 62.7% (52) | 59.1% (26) | 66.7% (26) | |
| 2 | 3.6% (3) | 6.8% (3) | 0.0% (0) | |
| CTP | A | 79.5% (66) | 72.7% (32) | 87.2% (34) |
| B | 15.7% (15) | 20.5% (9) | 10.3% (4) | |
| No cirrhosis | 4.8% (4) | 6.8% (3) | 2.6% (1) | |
| BCLC stage | A/B | 50.0% (16) | ||
| C | 47.7% (17) | |||
| — | 2.3% (1) | |||
| CLIP score | 0-1 | 68.2% (30) | ||
| ≥ 2 | 31.8% (12) | |||
| — | 0.0% (0) | |||
| Tumor vascular thrombosis | Yes | 28.9% (24) | 29.5% (15) | 28.2% (11) |
| Disease status | Locally recurrent | 6.0% (5) | 9.1% (4) | 2.6% (1) |
| Newly diagnosed | 94.0% (78) | 90.9% (40) | 97.4% (38) | |
| No. of nodular tumors | 1 | 79.5% (66) | 72.7% (32) | 87.2% (34) |
| 2 | 15.7% (15) | 22.7% (10) | 7.7% (3) | |
| 3 | 4.8% (4) | 4.5% (2) | 5.1% (2) | |
| Longest tumor dimension, cm | 5.7 (1.9-12.0) | 5.0 (1.9-12.0) | 6.0 (2.2-10.9) | |
| Sum of longest tumor diameters, cm | 5.8 (1.9-12.0) | 5.7 (1.9-12.0) | 6.0 (2.4-10.9) | |
| Biochemical analysis | ||||
| Total bilirubin, mg/dL | 0.7 (0.2-3.2) | 0.8 (0.2-3.2) | 0.6 (0.2-3.2) | |
| Platelets, k/UL | 151.0 (55.0-463.0) | 132.5 (55.0-336.0) | 183.0 (59.0-463.0) | |
| AFP, ng/mL* | 7.0 (1.3-66,081) | 18.6 (1.3-66,081) | 4.6 (1.3-461.9) | |
| CA-19.9 (u/mL)† | 38.1 (0.0-10549) | 31.0 (0.0-398.0) | 72.0 (0.0-10549) | |
| Previous therapy | ||||
| Any surgical resection | Yes | 4.8% (4) | 6.8% (3) | 2.6% (1) |
| Any transarterial chemoembolization | Yes | 6.0% (5) | 11.4% (5) | 0.0% (0) |
| Any radiofrequency ablation | Yes | 2.4% (2) | 2.3% (1) | 2.6% (1) |
| Any chemotherapy | Yes | 32.5% (27) | 6.8% (3) | 61.5% (24) |
| Any other | Yes | 15.7% (15) | 9.1% (4) | 23.1% (9) |
| None | Yes | 54.2% (45) | 68.2% (30) | 38.5% (14) |
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CA-19.9, cancer antigen 19.9; CLIP, Cancer of the Liver Italian Program; CTP, Child-Turcotte-Pugh; ECOG, Eastern Cooperative Oncology Group; EtOH, ethyl hepatocellularalcohol; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis.
*
n = 82.
†
n = 76.